Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22055470 | 1.00 | EPHX1 (1.00) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL21442929 | 1.00 | EPHX1 (1.00) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL24490081 | 1.00 | EPHX1 (1.00) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL24574267 | 1.00 | EPHX1 (1.00) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL16437128 | 0.98 | EPHX1 (0.96) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL27192692 | 0.96 | EPHX1 (0.92) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL22813414 | 0.89 | EPHX1 (0.80) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL1698332 | 0.88 | EPHX1 (0.79) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL6473627 | 0.87 | EPHX1 (0.76) | EPHX1HPGDKMT2ALMNASMN1; SMN2 | |
| SCHEMBL1698397 | 0.87 | EPHX1 (0.76) | EPHX1HPGDKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188263-A1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | claimed |
| WO-2009027264-A1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-05 | — | — | WO | claimed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815951-B2 | Inhibitors of epoxide hydrolases for the treatment of inflammation | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2188263-A1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | F. Hoffmann-Roche AG (CH) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009027264-A1 | BENZIMIDAZOLE DERIVATIVES USED AS FXR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-05 | — | — | WO | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-05-24 | — | — | US | disclosed |
| US-3968211-A | Compositions and methods of use of amidines for anti-arrhythmic purposes | THE UPJOHN COMPANY (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245331-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF HYPERTENSION | EPHX1, EPHX2, NCEH1 | EPHX1 1/4885HPGD 40/4885KMT2A 2538/4885 |
| US-20070117782-A1 | INHIBITORS OF EPOXIDE HYDROLASES FOR THE TREATMENT OF INFLAMMATION | EPHX1, LTA4H, PTGS1 | EPHX1 1/4885HPGD 51/4885KMT2A 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.